Advisory and Editorial Board
The Advisory and Editorial Board of ADC Review / Journal of Antibody-drug Conjugates is comprised of physicians and industry experts/Key Opinion Leaders (KOL) from a broad range of backgrounds and expertise.
Accomplished in areas including clinical oncology and hematology practice innovation and management, public policy, professional advocacy and education, our Advisory Board members are able to combine their passion and know-how for medical research and drug development to create tremendous value for all members of our international network.
Our Advisory Board members are actively managing successful clinical practices, teaching at major universities and hospitals, holding senior management positions at medical associations, research institutes / laboratories, pharmaceutical and life-science companies, governmental agencies and major insurance companies.
Our Advisory Board brings an impressive level of healthcare experience to our publication, enabling us to offer innovation, education, advocacy and best practices to our members. Each Advisory Board member is involved in helping us publish a broad range of topics and timely news updates in the field of Antibody-drug Conjugates.
Join our Advisory Board
To join our Advisory Board, contact us: email@example.com
Charles Afram, MSc, BSc
Medical Advisor Oncology at OnocNeth Partners and Nordic Pharma.
Read full profile
Clifford S. Mintz, PhD
A seasoned bioscience professional with over 18 years of experience in drug discovery/development, biomanufacturing, commercialization and regulatory compliance. Dr Mintz is also a professional medical/healthcare writer and a regular contributor to life sciences business publications. Read full profile
Alain Beck, Ph.D
Senior Director Antibody and ADC Physico-Chemistry Centre d’Immunologie Pierre Fabre (CIPF) (Alain is also member of the World ADC Advisory Board).
Read full profile
Don S. Dizon, MD, FACP
Associate Professor of Obstetrics & Gynecology, Department: Obstetrics & Gynecology and Medicine, Brown University, Division of Biology and Medicine. Read full profile
Laurent Ducry, Ph.D
Ducry is leading the antibody-drug conjugates R&D group of Lonza. He is also the editor of “Antibody-Drug Conjugates: Methods and Protocols” (Springer, Humana Press, 2013). Read full profile
Alain Herrera, MD
Consultant in Oncology and Associate Director at Kephren in Paris, France.
Read full profile
Maria Fe Paz, MSc, Ph.D
Maria Fe Paz is, the Chief Medical Officer of Diaceutics Group responsible for the development of clinical and laboratory partnerships. Read full profile
Michael Molony is currently Director, Analytical Development – ADC at Ajinomoto Althea, Inc. Read full profile
Prathap Kumar Mahalingaiah, DVM, MS, PhD, DABT
Prathap Kumar Mahalingaiah, DVM, MS, PhD, DABT is currently Senior Scientist
Senior Scientist, Investigative Toxicology and Pathology at Abbvie. Read full profile
Sanjay Nilapwar, Ph.D
Sanjay Nilapwar, Ph.D, works as Purification Process Scientist in Novel Molecules group of Medimmune, Gaithersburg and is also part of platform ADC CMC development team. Read full profile
David Rabuka, Ph.D
David Rabuka is currently the Global Head of R&D, Chemical Biology at Catalent Pharma. Read full profile
Thomas Rohrer, BS, MS
Head of Antibody Drug Conjugation Project Evaluation at Lonza, has 30 years of experience in development, scale-up and manufacturing. Read full profile
Thomas Shellenberger, MD
Surgical oncologist who focuses on cancers of and neck. Read full profile
Ruta Waghmare, Ph.D
Ruta Waghmare (Ph.D) is the current Director, World Wide Emerging Biotech Market Sales Development, Global Pharma Processing at MilliporeSigma, a business of Merck KGaA, Darmstadt, Germany. Read full profile
Mark Wright BSc, Ph.D
Mark Wright (BSc, Ph.D) is the Site Lead for Primal Healthcare UK’s ADC conjugation unit in Grangemouth, UK, and has over 15 years experience in biopharmaceutical production and protein conjugation Read full profile
Judith Wolf, MD
Board Certified Oncologists who received her medical education from the Northeastern Ohio Universities College of Medicine and the University of Texas Health Science Center at Houston. Read full profile
Cynthia Wooge, Ph.D
Cynthia Wooge (Ph.D) has been in the pharmaceutical contract manufacturing for over 20 years, with diverse experience including custom product development, technology transfer, process validation to business development. Cynthia is currently in Global Strategic Marketing for SAFC. Read full profile
Cecilia Zapata-Harms, MS, MHA
Cecilia Zapata-Harms (MS, MHA) is chief visionary office at ELEV8BIO. She has held leadership positions in strategy, joint venture startup and program administration. Her career spans more than 25+ years in life science/biotechnology and healthcare industry. Read full profile
Weixing (Star) Zhang, Ph.D
Medicinal chemist; Roche R&D Center (China) Ltd Read full profile
Last Editorial Review: August 21, 2016
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
Topics to be Covered Introduction To Antibody Conjugates Overview Of Techniques In Quantitative Pharmacology No Such Thing As A Magic Bullet: The Hidden Challenges Of ADC Discovery And Development...